“We are pleased to welcome Feng to our Board—he brings deep expertise in investment strategy and capital markets across multiple industries,” said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. “We look ...

GEAR-NK cells are designed to work alongside monoclonal ... "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities ...

Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants.NKGen Biotech, Inc. (“NKGen” or the “Company”) ...

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural ...

The patient will receive troculeucel infusions and undergo regular independent assessments by Dr. Sigounas at GWU Medical Center.

Second, third generation leaders shape future of South Koreas pharmaceutical industry New leadership emerges as South Koreas ...

REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...

While initially met with skepticism, our innovative approach using one’s own enhanced NK cells to improve proteins ... the meaning of Section 27A of the Securities Act and Section 21E of the ...

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK” ...

GT Biopharma Dr. Miller will speak to the mechanisms by which tri-specific engagers enhance NK cell activity, their unique ability to work synergistically with NK cells to improve cytotoxicity and ...